Location: United States, Massachusetts, Waltham
Employees: 11-50
Total raised: $230M
Investors 1
| Date | Name | Website |
| 11.04.2022 | Atlas Vent... | atlasventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.12.2025 | Series B | $120M | - |
| 09.04.2022 | Series A | $110M | - |
Mentions in press and media 6
| Date | Title | Description |
| 03.12.2025 | Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic | Triana Biomedicines has tapped Pfizer Ventures and a number of other existing and new investors to secure a $120 million series B the biotech will use to take its lead molecular glue degrader into the clinic. The latest funding round was co... |
| 03.12.2025 | Triana Biomedicines Raises $120M in Series B Financing | TRIANA Biomedicines, Inc., a Lexington, MA-based biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform, raised $120M in Series B financing. The round was led by Ascenta Capital a... |
| 23.06.2022 | TRIANA Biomedicines Attracts Leading Protein Science and Clinical Oncology Experts to its Scientific Advisory Board | Robert A. Copeland, PhD and Adrian M. Senderowicz, MD join Scientific Advisory Board WALTHAM, MA / ACCESSWIRE / June 23, 2022 / TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on building a target-first and r... |
| 09.04.2022 | Triana Biomedicines Raises $110M In Series A Funding | Triana Biomedicines, a Boston, MA-based biotechnology company, raised $110M in Series A funding. The round was led by Lightspeed Venture Partners with participation from Pfizer Ventures, Surveyor Capital and Logos Capital. The company inten... |
| 06.04.2022 | TRIANA Biomedicines Launches With $110M | BOSTON, MA, TRIANA Biomedicines announced their launch with $110 million in total funding. >> Click here for more funding data on TRIANA Biomedicines >> To export TRIANA Biomedicines funding data to PDF and Excel, click here... |
| - | Triana Biomedicines | “TRIANA Biomedicines discovers and develops molecular glue therapeutics employing a target first and rational molecular glue discovery platform and focusing on degradation of high-profile cancer targets.” |